Silo Pharma Launches $11.7M Private Placement, Deepening Dilution Risk
SILO sits 90% above its 52-week low of $3.315.
Summary
Silo Pharma is raising up to $11.7 million through a private placement, a highly dilutive move for a company with a market cap of just $8.7 million. The offering follows a 1-for-15 reverse split in June and a pending shareholder vote to increase authorized shares from 6.67 million to 250 million — a clear signal of aggressive equity financing. With a 12-month cash runway reported in May, this raise suggests either accelerated spending or a desire to shore up the balance sheet ahead of potential milestones. The terms of the placement, including pricing and warrant coverage, are not yet disclosed, but the size relative to the company's valuation is substantial. The proceeds will be used for working capital and general corporate purposes. Investors should watch for the final pricing and any updates on the shareholder vote, which could further enable dilution.
At the time of this announcement, SILO was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $3.32 to $15.15. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.